Cart
sales@molnova.com
MLi-2
CAS No. 1627091-47-7
MLi-2( MLi2 | Mli 2 )
Catalog No. M12407 CAS No. 1627091-47-7
A potent, selective, orally available and brain-penetrant LRRK2 inhibitor with kinase IC50 of 0.76 nM, cellular IC50 of 1.4 nM (dephosphorylation of LRRK2 pSer935 LRRK2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 138 | In Stock |
|
| 2MG | 77 | In Stock |
|
| 5MG | 128 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 432 | In Stock |
|
| 50MG | 639 | In Stock |
|
| 100MG | 910 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMLi-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally available and brain-penetrant LRRK2 inhibitor with kinase IC50 of 0.76 nM, cellular IC50 of 1.4 nM (dephosphorylation of LRRK2 pSer935 LRRK2).
-
DescriptionA potent, selective, orally available and brain-penetrant LRRK2 inhibitor with kinase IC50 of 0.76 nM, cellular IC50 of 1.4 nM (dephosphorylation of LRRK2 pSer935 LRRK2); displays >295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels; signficantly reduces the ratio of phosphorylated Ser935 LRRK2 (pS935) to total LRRK2 in the mouse cortex, consistent with enlarged type II pneumocytes.
-
In Vitro——
-
In Vivo——
-
SynonymsMLi2 | Mli 2
-
PathwayAutophagy
-
TargetLRRK2
-
RecptorLRRK2
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number1627091-47-7
-
Formula Weight379.4555
-
Molecular FormulaC21H25N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 26 mg/mL
-
SMILESCC1(OC2=CC3=C(NN=C3C4=CC(N5C[C@H](C)O[C@H](C)C5)=NC=N4)C=C2)CC1
-
Chemical Name1H-Indazole, 3-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-methylcyclopropyl)oxy]-, rel-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Scott JD, et al. J Med Chem. 2017 Apr 13;60(7):2983-2992.
2. Fell MJ, et al. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409.
3. Volpicelli-Daley LA, et al. J Neurosci. 2016 Jul 13;36(28):7415-27.
molnova catalog
related products
-
PFE-360
PFE-360 is a novel potent, selective, brain-penetrating LRRK2 inhibitor with IC50 of 3 nM.
-
LRRK2-IN-7
LRRK2-IN-7 is a selective, CNS permeable and potent LRRK2 kinase inhibitor (IC50: 0.9 nM) for the study of Parkinson's disease.
-
GSK2578215A
GSK2578215A is a highly potent, selective, BBB-permeable LRRK2 inhibitor with IC50 of 10.9 and 9.9 nM for wild-type LRRK2 and the G2019S mutant, respectively.
